Cargando…
The expanding role of IAP antagonists for the treatment of head and neck cancer
Inhibitors of apoptosis proteins (IAPs) inhibit the intrinsic and extrinsic cell death pathways, promoting cell survival. Antagonists of these pathways are under study as anti‐cancer therapeutics. A high proportion of head and neck squamous cell carcinomas (HNSCCs) have genomic alterations in IAP pa...
Autores principales: | Kansal, Vikash, Kinney, Brendan L. C., Uppada, Srijayaprakash, Saba, Nabil F., Stokes, William A., Buchwald, Zachary S., Schmitt, Nicole C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358233/ https://www.ncbi.nlm.nih.gov/pubmed/37132167 http://dx.doi.org/10.1002/cam4.6011 |
Ejemplares similares
-
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
por: Kansal, Vikash, et al.
Publicado: (2023) -
ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer
por: Ye, Wenda, et al.
Publicado: (2020) -
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
por: Gomez‐Roca, Carlos, et al.
Publicado: (2021) -
Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017) -
Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)